Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.